Zymeworks Goodwill and Intangible Assets 2016-2024 | ZYME

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zymeworks goodwill and intangible assets from 2016 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zymeworks goodwill and intangible assets from 2016 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$146.3B
Gilead Sciences (GILD)	$114.5B
Bristol Myers Squibb (BMY)	$114.2B
Vertex Pharmaceuticals (VRTX)	$108.7B
CSL (CSLLY)	$83.4B
Regeneron Pharmaceuticals (REGN)	$74.9B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.7B
Alnylam Pharmaceuticals (ALNY)	$31.8B
BioNTech SE (BNTX)	$26.8B
Illumina (ILMN)	$21.7B
BeiGene (ONC)	$20.5B
Biogen (BIIB)	$20.5B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.8B
Genmab (GNMSF)	$13.7B
Intra-Cellular Therapies (ITCI)	$13.4B
Moderna (MRNA)	$13.1B
Insmed (INSM)	$13B
Bio-Techne Corp (TECH)	$12B
BioMarin Pharmaceutical (BMRN)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
Vaxcyte (PCVX)	$10.6B
QIAGEN (QGEN)	$10.5B
Exelixis (EXEL)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exact Sciences (EXAS)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.5B
Repligen (RGEN)	$9B
Roivant Sciences (ROIV)	$8.1B